What is severe asthma?
Asthma which requires the use of high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy. 1 (International European Respiratory Society [ERS] and American Thoracic Society [ATS] Task Force.)
Patients with refractory disease either remain uncontrolled despite their treatment being optimised or require high doses of controller and reliever medication to maintain control. 2
The eosinophilic asthma phenotype has been shown to be associated with asthma severity, late-onset disease and steroid refractoriness. 4
By characterising a patient’s severe asthma phenotype, they can be treated differently with personalised and targeted therapies, and outcomes could be improved. 4
Prevalence and burden
Severe asthma patients are at high risk of having a severe exacerbation and are often dependent on oral corticosteroids. 4
Nucala is an anti-IL-5 treatment that specifically targets the eosinophilic phenotype.
- Chung KF, Wenzel SE, Brozek JL et al. Eur Respir J 2014;43:343–373.
- Peters S P, Ferguson G, Deniz Y et al. Respir med 2006;100:1139–1151.
- Walford H et al. E Journal Asthma Allergy 2014;11(7): 53-56
- Hoskins G, McCowan C, Neville RG. et al. Thorax 2000;55:19–24.
- Campo P, Rodriguez F, Sánchez-García et al. J Investig Allergol Clin Immunol 2013;23:76–88.
- Nucala Summary of Product Characteristics. Available from www.medicines.ie Last accessed: May 2020
- Walford H, Doherty T. J Asthma Allergy 2014;11:53–65.